148 related articles for article (PubMed ID: 25758549)
1. Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia.
Chiliza B; Asmal L; Kilian S; Phahladira L; Emsley R
Hum Psychopharmacol; 2015 May; 30(3):173-82. PubMed ID: 25758549
[TBL] [Abstract][Full Text] [Related]
2. Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects.
Emsley R; Chiliza B; Asmal L; Kilian S; Riaan Olivier M; Phahladira L; Ojagbemi A; Scheffler F; Carr J; Kidd M; Dazzan P
Schizophr Res; 2017 Oct; 188():144-150. PubMed ID: 28130002
[TBL] [Abstract][Full Text] [Related]
3. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.
Crespo-Facorro B; Pelayo-Terán JM; Pérez-Iglesias R; Ramírez-Bonilla M; Martínez-García O; Pardo-García G; Vázquez-Barquero JL
J Psychiatr Res; 2007 Oct; 41(8):659-66. PubMed ID: 16797591
[TBL] [Abstract][Full Text] [Related]
4. Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders.
Phahladira L; Asmal L; Kilian S; Chiliza B; Scheffler F; Luckhoff HK; du Plessis S; Emsley R
Schizophr Res; 2019 Apr; 206():394-399. PubMed ID: 30385130
[TBL] [Abstract][Full Text] [Related]
5. [Minor neurological and physical anomalies in patients with first-episode psychosis].
Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
[TBL] [Abstract][Full Text] [Related]
6. Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting.
Chiliza B; Ojagbemi A; Esan O; Asmal L; Oosthuizen P; Kidd M; Gureje O; Emsley R
Early Interv Psychiatry; 2016 Feb; 10(1):54-62. PubMed ID: 24690088
[TBL] [Abstract][Full Text] [Related]
7. Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study.
Crespo-Facorro B; de la Foz VO; Ayesa-Arriola R; Pérez-Iglesias R; Mata I; Suarez-Pinilla P; Tabares-Seisdedos R; Vázquez-Barquero JL
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():162-7. PubMed ID: 23435091
[TBL] [Abstract][Full Text] [Related]
8. An investigation of a possible relationship between olfactory identification deficits at first episode and four-year outcomes in patients with psychosis.
Good KP; Tibbo P; Milliken H; Whitehorn D; Alexiadis M; Robertson N; Kopala LC
Schizophr Res; 2010 Dec; 124(1-3):60-5. PubMed ID: 20692126
[TBL] [Abstract][Full Text] [Related]
9. Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment.
Emsley R; Asmal L; du Plessis S; Chiliza B; Phahladira L; Kilian S
Psychol Med; 2017 Sep; 47(12):2187-2196. PubMed ID: 28347393
[TBL] [Abstract][Full Text] [Related]
10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
11. Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia.
Emsley R; Asmal L; Rubio JM; Correll CU; Kane JM
Schizophr Res; 2020 Nov; 225():55-62. PubMed ID: 31767510
[TBL] [Abstract][Full Text] [Related]
12. Prolactin, flupenthixol decanoate and first episode schizophrenia - clinical and laboratory correlates.
Retief M; Chiliza B; Phahladira L; Emsley R; Asmal L
Metab Brain Dis; 2019 Dec; 34(6):1679-1687. PubMed ID: 31422510
[TBL] [Abstract][Full Text] [Related]
13. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.
Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R
Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186
[TBL] [Abstract][Full Text] [Related]
14. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
15. Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project.
Bola JR; Lehtinen K; Aaltonen J; Räkköläinen V; Syvälahti E; Lehtinen V
J Nerv Ment Dis; 2006 Oct; 194(10):732-9. PubMed ID: 17041284
[TBL] [Abstract][Full Text] [Related]
16. Trajectories and antecedents of treatment response over time in early-episode psychosis.
Levine SZ; Rabinowitz J
Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
[TBL] [Abstract][Full Text] [Related]
17. Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort.
McGregor N; Thompson N; O'Connell KS; Emsley R; van der Merwe L; Warnich L
Psychiatry Res; 2018 Apr; 262():141-148. PubMed ID: 29448178
[TBL] [Abstract][Full Text] [Related]
18. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
[TBL] [Abstract][Full Text] [Related]
19. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
Honer WG; Kopala LC; Rabinowitz J
J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
[TBL] [Abstract][Full Text] [Related]
20. Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis.
Hui CL; Wong GH; Tang JY; Chang WC; Chan SK; Lee EH; Lam MM; Chiu CP; Law CW; Chung DW; Tso S; Pang EP; Chan KT; Wong YC; Mo FY; Chan KP; Hung SF; Honer WG; Chen EY
Schizophr Res; 2013 Oct; 150(1):297-302. PubMed ID: 23993865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
